184 related articles for article (PubMed ID: 17711511)
21. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
Campos-Fernandes JL; Bastien L; Nicolaiew N; Robert G; Terry S; Vacherot F; Salomon L; Allory Y; Vordos D; Hoznek A; Yiou R; Patard JJ; Abbou CC; de la Taille A
Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
[TBL] [Abstract][Full Text] [Related]
23. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
[TBL] [Abstract][Full Text] [Related]
24. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
25. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
27. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice.
Ng TK; Vasilareas D; Mitterdorfer AJ; Maher PO; Lalak A
BJU Int; 2005 Mar; 95(4):545-8. PubMed ID: 15705077
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
[TBL] [Abstract][Full Text] [Related]
30. An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men.
Borden LS; Wright JL; Kim J; Latchamsetty K; Porter CR
BJU Int; 2007 Mar; 99(3):559-63. PubMed ID: 17155976
[TBL] [Abstract][Full Text] [Related]
31. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital.
Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO
West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288
[TBL] [Abstract][Full Text] [Related]
33. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
34. [The general practitioner's part in the initiation of diagnostic procedures in prostate cancer].
Braun KP; May M; Grassmel Y; Führer S; Hoschke B; Braun V
Aktuelle Urol; 2008 Mar; 39(2):141-6. PubMed ID: 18379968
[TBL] [Abstract][Full Text] [Related]
35. [Repeat prostate biopsy in patients with previous negative biopsies].
Nagata M; Sato T; Un-no T; Nagae H; Mugiya S; Takayama T; Suzuki K; Fujita K
Hinyokika Kiyo; 2002 Oct; 48(10):589-92. PubMed ID: 12491609
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive detection of prostate cancer by electromagnetic interaction.
Bellorofonte C; Vedruccio C; Tombolini P; Ruoppolo M; Tubaro A
Eur Urol; 2005 Jan; 47(1):29-37; discussion 37. PubMed ID: 15582246
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
Chun FK; Müller I; Lange I; Friedrich MG; Erbersdobler A; Karakiewicz PI; Graefen M; Pantel K; Huland H; Schwarzenbach H
BJU Int; 2006 Sep; 98(3):544-8. PubMed ID: 16925751
[TBL] [Abstract][Full Text] [Related]
38. Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
Celhay O; de la Taille A; Salomon L; Doré B; Irani J
BJU Int; 2007 May; 99(5):1028-30. PubMed ID: 17324221
[TBL] [Abstract][Full Text] [Related]
39. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N; Fleshner N
BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
[TBL] [Abstract][Full Text] [Related]
40. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
Dai B; Ye DW; Kong YY; Shen YJ; Wang BH
Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]